loader
Please Wait
Applying Filters...

Parand Darou Pharma Parand Darou Pharma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Volasertib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Volasertib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    2D Structure
    1. Also known as: 755038-65-4, Bi 6727, Volasertib (bi 6727), Bi-6727, Bi6727 (volasertib), Volasertib [usan]
    Molecular Formula
    C34H50N8O3
    Molecular Weight
    618.8  g/mol
    InChI Key
    SXNJFOWDRLKDSF-XKHVUIRMSA-N
    FDA UNII
    6EM57086EA
    Volasertib is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide
    2.1.2 InChI
    InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1
    2.1.3 InChI Key
    SXNJFOWDRLKDSF-XKHVUIRMSA-N
    2.1.4 Canonical SMILES
    CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
    2.1.5 Isomeric SMILES
    CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
    2.2 Other Identifiers
    2.2.1 UNII
    6EM57086EA
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Bi 6727

    2. Bi-6727

    2.3.2 Depositor-Supplied Synonyms

    1. 755038-65-4

    2. Bi 6727

    3. Volasertib (bi 6727)

    4. Bi-6727

    5. Bi6727 (volasertib)

    6. Volasertib [usan]

    7. 6em57086ea

    8. Volasertib (usan)

    9. Bi6727

    10. Bi6727(volasertib)

    11. Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-

    12. N-((1s,4s)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide

    13. N-(trans-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide

    14. N-{trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7r)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide

    15. Volasertib [usan:inn]

    16. Unii-6em57086ea

    17. Ibi

    18. N-(trans-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((7r)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide

    19. Bi6727,volasertib

    20. Volasertib(bi6727)

    21. Volasertib [inn]

    22. Bi6727 - Volasertib

    23. Volasertib [who-dd]

    24. Mls006011195

    25. Schembl738946

    26. Gtpl7947

    27. Schembl2169101

    28. Schembl9888052

    29. Chembl1233528

    30. Chembl4284151

    31. Schembl21916558

    32. Bcpp000341

    33. Dtxsid801099395

    34. Dtxsid901025694

    35. Bcp02405

    36. Ex-a1364

    37. Bdbm50402023

    38. Mfcd20926414

    39. Nsc757149

    40. Nsc800965

    41. S2235

    42. Zinc39716290

    43. Akos030257530

    44. Zinc100071772

    45. Zinc248087828

    46. Bcp9000403

    47. Ccg-264952

    48. Cs-0274

    49. Db12062

    50. Nsc-757149

    51. Nsc-800965

    52. Ncgc00263087-01

    53. Ncgc00263087-02

    54. Ncgc00263087-03

    55. Ncgc00263087-12

    56. Ncgc00263087-15

    57. Ncgc00485964-01

    58. Ac-32844

    59. As-16996

    60. Hy-12137

    61. N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7r)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7h-pteridin-2-yl]amino]-3-methoxybenzamide

    62. Smr004702964

    63. Sw218140-2

    64. D10182

    65. Sr-03000003275

    66. Q7939986

    67. Sr-03000003275-1

    68. 755038-54-1

    69. N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide

    70. N-[cis-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide

    71. N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 618.8 g/mol
    Molecular Formula C34H50N8O3
    XLogP34.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count10
    Exact Mass618.40058749 g/mol
    Monoisotopic Mass618.40058749 g/mol
    Topological Polar Surface Area106 Ų
    Heavy Atom Count45
    Formal Charge0
    Complexity996
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of acute myeloid leukaemia

    Post Enquiry
    POST ENQUIRY